Literature DB >> 30109540

Correction to: Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy.

Rudolf A Werner1,2, Harun Ilhan3, Sebastian Lehner3,4, László Papp5, Norbert Zsótér6, Imke Schatka7, Dirk O Muegge2, Mehrbod S Javadi1, Takahiro Higuchi2,8, Andreas K Buck2, Peter Bartenstein3, Frank Bengel9, Markus Essler10, Constantin Lapa2, Ralph A Bundschuh11.   

Abstract

The article "Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy," was originally published electronically on the publisher's internet portal without open access.

Entities:  

Year:  2018        PMID： 30109540     DOI： 10.1007/s11307-018-1261-4

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN： 1536-1632            Impact factor:   3.488


  3 in total

Review 1.  Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy?

Authors:  Susanne Lütje; Georg Feldmann; Markus Essler; Peter Brossart; Ralph A Bundschuh
Journal:  J Nucl Med       Date:  2020-01-10       Impact factor: 10.057

2.  Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.

Authors:  Kyle Current; Catherine Meyer; Clara E Magyar; Christine E Mona; Joel Almajano; Roger Slavik; Andreea D Stuparu; Chloe Cheng; David W Dawson; Caius G Radu; Johannes Czernin; Katharina Lueckerath
Journal:  Clin Cancer Res       Date:  2020-01-13       Impact factor: 12.531

Review 3.  Therapy of Patients with Neuroendocrine Neoplasia-Evidence-Based Approaches and New Horizons.

Authors:  Ralph A Bundschuh; Bilel Habacha; Susanne Lütje; Markus Essler
Journal:  J Clin Med       Date:  2019-09-16       Impact factor: 4.241
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.